Sandia National Laboratories has published an article on the longstanding and productive collaboration between Sandia’s Center for Integrated Nanotechnologies (CINT) and Imagion Biosystems’ R&D scientists.
Highlights of the collaboration cited in the article include Sandia scientists’ contributions to nanoparticle size and shape analysis, the co-development of a new process for high-yield, precise-size nanoparticle production, and the successful transfer of the process to Imagion Biosystems’ clinical-trials nanoparticles manufacturing partner, ChemConnection.
Read Magnetic nanoparticles leap from lab bench to breast cancer clinical trials at Sandia National Laboratories.
Imagion Appoints New Non-Executive Director, Brett Mitchell
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, today announced the appointment of Mr Brett Mitchell